Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 154

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 154
---
 of allowance for credit losses of $11,249 and $13,901 as of December 31, 2024 and December 31, 2023, respectively277,760 274,504 Collateral on foreign currency forward contract2,750 2,750 Marketable investments580 48 Deferred tax assets, net23,484 28,290 Warrant assets4,366 1,759 Intangible assets, net— 6,487 Property and equipment, net48 5,438 Other non-current assets2,993 3,109 Total assets$332,235 $334,254 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued liabilities$2,810 $3,935 Liabilities held for sale (Note 7)1,255 — Deferred income1,500 9 Total current liabilities5,565 3,944 Contingent consideration payable— 4,900 Unsecured senior notes, net31,412 30,781 Revolving credit facility6,233 12,350 Other non-current liabilities335 1,964 Total liabilities43,545 53,939 Commitments and contingencies (Note 9)Stockholders' equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding— — Common stock, $0.001 par value; 250,000,000 shares authorized; 12,213,599 and 12,497,770 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively12 12 Additional paid-in capital4,419,991 4,425,104 Accumulated deficit(4,131,313)(4,144,801)Total stockholders' equity288,690 280,315 Total liabilities and stockholders' equity$332,235 $334,254  

See accompanying notes to the consolidated financial statements.

34

SWK HOLDINGS CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)Year Ended December 31,20242023Revenues:Finance receivable interest income, including fees$40,787 $36,346 Pharmaceutical development 3,616 1,202 Other 584 212 Total revenues44,987 37,760 Cost